Gride-M Forte Tablet PR contains a combination of Glimepiride (2mg) and Metformin (500mg), formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake and utilization. The combination of these two agents provides complementary mechanisms of action, making Gride-M Forte Tablet PR effective in achieving glycemic control in patients inadequately managed by diet and exercise alone. This extended-release formulation allows for sustained drug release, promoting better patient compliance and stable plasma drug concentrations. It is indicated for adults with type 2 diabetes who require dual therapy to achieve target blood glucose levels. Gride-M Forte Tablet PR should be used in conjunction with lifestyle modifications such as diet and exercise. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and lactic acidosis, though the latter is rare. This medication should be prescribed and used under medical supervision.